who discovered glp-1 agonists Discovery of Biased Dual-Agonists of Glucagon-Like Peptide 1 and Glucagon Receptors through Mutation of a Conserved Aspartate LY3437943, a novel triple glucagon,
Description
A secondary analysis of the STEP-HFpEF and STEP-HFpEF DM trials involving 1145 obese T2DM-associated HFpEF patients showed that semaglutide reduced NT-proBNP levels and improved health status after 52 weeks [83]

doi:10.1007/s001250051335 119

Canadian Journal of Diabetes, 2017, 41(5): 524-535

Many pharmaceutical companies lack internal peptide manufacturing at commercial scale

GLP-1 medications, by comparison, cost $800$1,200 per month, adding up to $10,000+ yearly, making surgery more cost-effective long-term

Post hoc analysis of SURPASS-CVOT trial has implications for future cardiovascular outcome trials Image content: This image is available to view online